Maynard Um
-
-
-
-
-
-
-
UBS Starts SAB Biotherapeutics (SABS) at Buy
-
-
-
-
-
-
-
SAB Biotherapeutics (SABS) PT Lowered to $12 at Chardan Capital Markets
-
-
-
-
-
-
-
SAB Biotherapeutics (SABS) Misses Q2 EPS by 79c
-
401,645 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

